A phase I/II, double-blind, placebo-controlled study assessing the safety and efficacy of AVX-012 ophthalmic solution in subjects with mild-to-moderate dry eye syndrome
Phase of Trial: Phase I/II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs AVX 012 (Primary)
- Indications Dry eyes
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors AVX Pharma
- 23 Oct 2017 Planned End Date changed from 1 Jan 2018 to 1 Oct 2018.
- 23 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 May 2018.
- 13 Jul 2017 According to an Avizorex Pharma media release, the phase II portion of this trial has been initiated.